Glioblastoma is the most common primary malignant brain tumour. Survival is poor and improved treatment options are urgently needed. Although immunotherapies have emerged as effective treatments for a number of cancers, translation of these through to brain tumours is a distinct challenge, particularly due to the blood–brain barrier and the unique immune tumour microenvironment afforded by CNS-specific cells. This review discusses the immune system within the CNS, mechanisms of immune escape employed by glioblastoma, and the immunological effects of conventional glioblastoma treatments. Novel therapies for glioblastoma that harness the immune system and their current clinical progress are outlined, including cancer vaccines, T-cell therapies and immune checkpoint modulators.

In this review, we describe the features of the immune system in the CNS, discuss the immune evasion strategies of glioblastoma, the molecular properties of its microenvironment, and the current clinical evidence supporting a role for immunomodulation in the treatment of glioblastoma.

**GLIOBLASTOMA TUMOUR MICROENVIRONMENT AND MECHANISMS OF IMMUNE ESCAPE**

Glioblastoma arises from glial cells, with surrounding brain parenchyma comprising CNS-specific cells including astrocytes, neurons and microglia, and a distinctive extracellular matrix (ECM) composition. Glioblastoma induces a TME characterised by immunosuppressive cytokines secreted by tumour cells, microglia and tumour-associated macrophages (TAMs). These factors, notably interleukin-6, interleukin-10, transforming growth factor-beta (TGF-β), and prostaglandin-E collectively inhibit both the innate and adaptive immune systems with suppression of NK activity and T-cell activation and proliferation, induction of T-cell apoptosis, downregulation of MHC expression, and skew of TAMs towards an M2 (immunosuppressive) phenotype. The TME is also characterised by tissue hypoxia provided by irregular vascularity and high-tumour oxygen consumption. Tissue hypoxia activates the immunosuppressive STAT3 pathway, leading to hypoxia-inducible factor-1 alpha (HIF-1α) synthesis, activation of regulatory T cells (T-reg) and production of vascular endothelial growth factor (VEGF), which can inhibit the maturation and function of dendritic cells. These mechanisms of immune escape are discussed below in more detail and summarised in Fig. 1.

**INTRODUCTION**

Glioblastoma is the most common primary malignant primary brain tumour in adults. Survival is poor, with a median survival of 14.6 months with standard treatment of surgical debulking followed by external-beam radiotherapy with concurrent temozolomide (TMZ) chemotherapy and adjuvant TMZ chemotherapy. In the last decade, clinical trials investigating targeted therapies have failed to demonstrate any significant improvement in survival, and innovative new treatments are urgently needed. Recently, focus has shifted towards novel strategies that modulate the immune response towards the tumour and the surrounding tumour microenvironment.

Recognition and eradication of malignant cells via immune surveillance of tumour-associated antigens (TAAs) is a key function of the immune system. TAAs typically represent peptides which are present within tumour cells but usually absent in the surrounding normal tissue. In glioblastoma, these antigens most commonly fall into three main classes; (i) aberrantly expressed non-mutated self-antigens, (ii) mutated self-antigens and (iii) unique antigens or neo-antigens - novel peptide sequences which are the result of somatic mutations in the cancer genome. Tumours manipulate the immune system to avoid detection of TAAs and to facilitate their own growth and survival.

Immunotherapy aims to harness the immune system against tumours, with breakthroughs observed in a number of cancers, most notably malignant melanoma and haematological malignancies. However, translating these approaches into therapies for primary brain tumours represents a distinct challenge due the unique tumour microenvironment and distinctive immune system within the CNS.

The CNS was traditionally considered immune privileged due to (i) the presence of the blood–brain barrier (BBB) that restricts access to immune cells, (ii) an absence of conventional lymphatic drainage restricting the trafficking of antigens to lymph nodes, (iii) a scarcity of specialised antigen-presenting cells, and (iv) downregulation of the major histocompatibility complex (MHC) expression in normal brain parenchyma, limiting antigen presentation. In recent years, this dogma has been eroded with substantial evidence now demonstrating that these interlinked factors tightly regulate a fully functional, innate and adaptive immune system within the CNS (Table 1).

In this review, we describe the features of the immune system in the CNS, discuss the immune evasion strategies of glioblastoma, the molecular properties of its microenvironment, and the current clinical evidence supporting a role for immunomodulation in the treatment of glioblastoma.
Extracellular matrix composition

ECM proteins commonly found in abundance in peripheral tissues including collagens, laminins and fibronectin are typically only associated with vascular basement membranes within the CNS. Instead, predominant ECM proteins in the glioma TME include glycoproteins, hyaluronic acid and heparan sulphate proteoglycans (HSPGs), which may be concentrated in cancer stem cell niches. HSPGs, in particular, are upregulated in glioblastoma and cause retention of heparin-binding angiogenic growth factors such as fibroblast growth factor (FGF) and VEGF, the local release of which promotes tumour angiogenesis and progression. Furthermore, glioma vasculature can upregulate the vessel-associated macromolecules peristin and tenasin C (TNC), which can promote tumour survival. These macromolecules can also promote immune evasion with TNC shown to block T-cell movement across glioma-associated blood vessels, preventing their migration into brain parenchyma. Peristin, when secreted by glioma stem cells, is able to promote recruitment of tumour-promoting macrophages from peripheral circulation.

Macrophages and microglia

Tumour-associated macrophages (TAMs), along with the resident CNS microglia, can constitute up to 30% of the tumour mass. Transcriptome analysis of TAMs has found that they may possess markers consistent with both M1 (classically activated or immunopressive) and M2 (alternatively activated or immunosuppressive) phenotypes, incongruous with the traditional M1/M2 dichotomy. TAM populations can be described both functionally and spatially. For example, CNS-resident microglia exist within the TME alongside distinct populations of bone marrow-derived macrophages (outlined in Table 1) and recent research has suggested that within the TME, bone marrow-derived macrophages may localise preferentially to the perivascular niche, while resident microglia localise to peritumoural regions. Accumulation of TAMs expressing CD163 (haemoglobin scavenger receptor) and CD204 (macrophage scavenger receptor), considered ‘M2’ phenotype markers, increases as tumour grade increases. In glioblastoma, higher CD163 TAM expression correlates with poorer outcomes. Cancer stem cells in glioblastoma are able to recruit TAMs by overexpression of the macrophage/microglia cytokine colony-stimulating factor-1 (CSF-1). This induces a pro-tumourgenic microenvironment via release of immunosuppressive factors such as IL-10 and overexpression of the indoleamine 2,3-dioxygenase (IDO) enzyme. TAMs also lack expression of key T-cell co-stimulation molecules and drive both tumour angiogenesis and resistance to anti-VEGF agents. Angiogenesis is driven through production of pro-angiogenic molecules including VEGF and FGF, with resistance to anti-angiogenics due to upregulation of alternative angiogenic pathways and stimulation of pericytes to proliferate in the perivascular niche. Pericytes are perivascular cells responsible for modulating blood flow, vessel permeability and remodelling, and their proliferation stabilises new vessels. TAMs can also enhance the invasiveness of glioma stem cells (GSCs) via the TGF-B1 signalling pathway. Further evidence, incongruous with the M1/M2 dichotomy, is that blockade of CSF-1R on the macrophage surface does not deplete glioblastoma TAMs in vivo, but leads to reprogramming of TAMs away from immunosuppressive phenotypes. Other emerging evidence includes the discovery of a link between tissue hypoxia and macrophage polarisation; with M1 macrophages present within normoxic tumour regions and M2 macrophages present in areas of hypoxia. These findings support the view that macrophage polarisation is not simply location dependent but instead dependent on distinct signals present in the local microenvironment. TAMs retain both plasticity and the ability to undergo reprogramming, characteristics which are potentially exploitable for therapeutic benefit.

Downregulation of MHC

An effective T-cell immune response requires antigen presentation and subsequent recognition, which is dependent on the co-expression of the human MHC proteins. Comparative analyses of gene expression profiles suggest that invading glioblastoma cells are able to escape immune recognition by downregulating expression of MHC molecules. The role of antigen presentation within the CNS is thought to fall primarily to the resident

| Characteristic | Current understanding |
|---------------|-----------------------|
| Blood–brain barrier | Leukocyte entry into the CNS is mediated by adhesion signals on endothelial cells (ECs) of the BBB. Limited expression of adhesion signals on ECs in healthy CNS results in low immune surveillance. In disease processes, infiltration of specific immune cell subsets is observed, which may be driven by BBB ECs or by immune cells within the CNS. While naïve T cell are absent within the CNS, activated T cells cross the BBB as patrolling memory T cells and regulatory T-cells; preventing inappropriate inflammation and facilitating myelin regeneration. |
| Lymphatic drainage | Extracellular fluid in the CNS is composed of cerebrospinal fluid (CSF) and interstitial fluid (ISF). CSF is mainly contained within the ventricular system and subarachnoid space, and drains directly into deep cervical and lumbar lymph nodes via lymphatic vessels associated with the nasal mucosa, dura mater and nerve roots. ISF is found in the extracellular spaces of CNS parenchyma and drains into cervical lymph nodes via intramural perivascular drainage pathways in cerebral artery walls. Both CSF and ISF may communicate within the brain lymphatic system via the glial lymphatic system, a perivascular channel system formed by astroglial cells which removes waste proteins and macromolecules. Tissue metabolites found within the glial lymphatic system traffic to deep cervical and lumbar lymph nodes via CSF. Within these lymph nodes, T cells may become primed and activated to recognise CNS-specific antigens. |
| Antigen-presenting cells | Three subsets of dural macrophage populations have been identified, named for their location in the CNS. Meningeal macrophages and choroid plexus macrophages are bone marrow derived, while perivascular macrophages appear to originate from haematopoietic stem cells in the embryonic yolk, an origin they share with microglial cells. These macrophage populations can all act as antigen-presenting cells. The position of perivascular macrophages allows them to sample both blood and CNS ISF, implying a possible role in communication between the CNS and periphery. As well as this, there is evidence from in vivo models that brain parenchyma is completely screened every few hours by resting microglia. |
| Antigen presentation via MHC expression | CNS antigen presentation is thought to occur at the BBB by microglia, dural macrophages or dendritic cells at so-called CNS ‘immune gateways’ where MHC is expressed. These gateways also act as entry ports for activated T cells, influx of which can be followed by monocyte recruitment that amplifies inflammatory reactions within CNS. |
microglia, with supporting evidence in vivo demonstrating that microglia are able to cross-present tumour antigens to CD8+ T cells via MHC Class I.34 However, the presence of immunosuppressive cytokines such as IL-10 and TGF-β within the glioblastoma TME cause microglia to lose MHC expression.11,35 Pericytes may also play a role in antigen presentation within the CNS, and pericyte MHC Class II expression is shown to increase in response to inflammatory cytokine release.36 In the TME, pericytes in contact with glioblastoma cells possess immunosuppressive functions evidenced by changes including a reduction in MHC expression and T-cell co-stimulatory signals.37 Low levels of MHC Class I molecules are also found on glioblastoma cancer stem cells, rendering them resistant to T-cell-mediated killing, and thus contributing towards tumour initiation, progression and resistance to therapy.38

T lymphocytes
In patients with glioblastoma, increased T-cell infiltration is found in both tumour (tumour-infiltrating lymphocyte; TIL) and brain parenchyma.39 Studies of human tumour samples have shown that this influx is counteracted with a number of events that evade the immune response including further downregulating MHC to prevent antigen presentation,40 increasing expression of the inhibitory protein programmed death ligand-1 (PD-L1),41 and increased recruitment of immunosuppressive regulatory T cells (Tregs) which express co-inhibitory molecules including cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor 1 (PD-1).42-44 Fourfold more Tregs are found in human glioblastoma samples than benign pituitary adenomas and meningiomas, with CTLA-4 expression on these T-regs threefold that on T-regs in peripheral blood.45 PD-L1 expression on

---

**Fig. 1** Immune gateways (left). In addition to the resident microglia, there are three distinct macrophage populations within the CNS present at so-called ‘immune gateways’ that act as ports of entry for activated T cells into the CNS. Perivascular macrophages, derived from the embryonic yolk sac, are located around parenchymal vessels (top). The other two populations, derived from bone marrow, are located in the meningeal spaces (middle) and the choroid plexus (bottom) (adapted from ref.156). Immune evasion in glioblastoma (right): the immunosuppressive tumour microenvironment (TME) of glioblastoma is the result of complex interactions between tumour cells, microglia, tumour-associated macrophages (TAMs), components of the extracellular matrix and tumour infiltrating lymphocytes (TILs), which are predominantly regulatory in phenotype (T-regs). Hypoxia promotes angiogenesis of abnormal blood vessels, further driving tumour growth (adapted from ref.10).
circuiting monocytes is significantly higher in patients with glioblastoma compared to healthy controls, while expression in tumour infiltrating monocytes is, on average, twice that of circulating monocytes from the same patient.\textsuperscript{41}

IMMUNOLOGICAL EFFECTS OF STANDARD THERAPY

Standard therapy for patients diagnosed with glioblastoma consists of maximal safe debulking surgery, followed by radiotherapy and temozolomide chemotherapy (RT-TMZ).\textsuperscript{2} In addition, high doses of glucocorticoids are frequently administered to reduce tumour-associated and radiotherapy-induced cerebral oedema. These therapies may potentially both augment or diminish immune responses.

Radiotherapy, chemotherapy and glucocorticoid therapy are independently immunosuppressive. Approximately 70\% of patients experience clinically significant reductions in their circulating CD4+ lymphocyte counts following standard treatment, persisting for up to a year and associated with early tumour progression.\textsuperscript{46} TMZ-induced lymphopenia is considered a significant limitation to clinical translation of immunotherapies.\textsuperscript{44} Radiation induces M2 macrophages and activation of TGF-β.\textsuperscript{45–47} RT-TMZ has been shown to increase PD-L1 expression in preclinical glioblastoma models, and acquired resistance to radiotherapy has been overcome by PD-L1 blockade in cancer models.\textsuperscript{48,53} Further, as well as depleting systemic lymphocyte counts, RT-TMZ also tilts the balance between regulatory and effector peripheral blood lymphocytes towards an immunosuppressive state.\textsuperscript{50,51} Corticosteroids dampen inflammatory cytokines, deplete T and B lymphocytes, reduce the effectiveness of anti-tumour therapy in rodent models, and their use is associated with poorer survival in patients with glioblastoma.\textsuperscript{52–54}

Conversely, standard treatments have been shown to induce immune responses through favourable modulation of the TME and ‘immunogenic cell death’. In addition to cancer cell death through DNA damage and free radical generation, radiation activates an interconnected chain of processes in the TME including inflammation, hypoxia, revascularisation, ECM remodeling and fibrosis.\textsuperscript{55} Radiation induces pro-inflammatory cytokines such as TNF-α, IL-1β, IFN-γ,CXCL9, CXCL10 and CXCL16 which recruit T cells.\textsuperscript{56–58} Sublethal doses of radiation promotes phenotypic changes in tumour cells that promote T-cell recognition and killing, including increasing expression of MHC Class I, co-stimulatory receptors, death receptors and heat-shock proteins.\textsuperscript{59–61} Further, evidence suggests RT is able to modulate the tumour vasculature and increase BBB permeability, leading to increased TIL trafficking.\textsuperscript{62} Abscopal responses (tumour response distant from the radiation field), while unusual, illustrate the potential for radiation-induced anti-tumour immunity.\textsuperscript{56,65} TMZ chemotherapy induces hypermutation of the tumour, and increased mutational load correlates with response to immune checkpoint inhibitors in a number of cancers including melanoma, NSCLC and urothelial cancers.\textsuperscript{66–71} Durable responses to nivolumab were observed in a case report of two patients with high mutational burden glioblastoma resultant from biallelic mismatch repair deficiency.\textsuperscript{72} In murine glioma models, TMZ has been found to increase priming of tumour antigen-specific CD4 and CD8 T cells.\textsuperscript{73,74} While associated with early progression, in one study of patients with glioblastoma, lymphopenia following TMZ was associated with better survival.\textsuperscript{73} Clinical evidence of immune-stimulation has been observed in vaccine trials of a dendritic cell vaccination where pre-treatment with RT-TMZ increased tumour antigen-specific T cells.\textsuperscript{75}

This delicate balance between stimulation or suppression of immune responses by standard therapies is still being elucidated. Potentially, careful timing to permit lymphocyte recovery, dose modification or local rather than systemic administration of standard therapies may permit immune priming of tumours without negation due to immunosuppressive sequelae.\textsuperscript{63,76} Recently, adding tumour-treating fields (alternating electric fields delivered via a transducer array applied to the scalp) to standard therapy has been shown to prolong survival.\textsuperscript{77} Whether this may enhance immune responses is unknown and further clinical trials are underway (Table 2).\textsuperscript{78}

IMMUNOTHERAPEUTIC APPROACHES AND CLINICAL PROGRESS IN GliOBLASTOMA

Early trials in glioblastoma largely administered systemic or intra-tumoural cytokines, with development limited by significant toxicity with only modest clinical benefit.\textsuperscript{79,80} Arguably the most promising of these, IFN-γ, possesses anti-proliferative, anti-angiogenic and pro-apoptotic functions and is able to increase antigen presentation through upregulation of MHC Class I and II, as well as mediating immune cell infiltration.\textsuperscript{81} However, IFN-γ also induces PD-L1 expression as well as promoting T-reg development. It is also possible that glioblastoma cells exploit IFN-γ through low level upregulation to induce PD-L1 expression and escape immune cell detection.\textsuperscript{82} These factors may help to explain why these early immunotherapeutic approaches were disappointing,\textsuperscript{83} and why current focus has moved towards therapies that either prime immune cells to target-specific tumour-associated antigens, or modulate the TME to reverse immune escape (Fig. 2). As yet, only two phase III trials have completed: the EGFRvIII-targeted vaccine rindopepimut in newly diagnosed glioblastoma; and the checkpoint inhibitor nivolumab in relapsed glioblastoma; with neither demonstrating survival advantage.\textsuperscript{84,85} Phase III trials of checkpoint inhibitors and dendritic cell vaccines are ongoing, with a large number of agents in earlier stages of clinical development including peptide vaccines, adoptive T-cell therapies, oncolytic viruses (OV) and combination therapies (Table 2).

Immune checkpoint inhibitors

The amplitude and quality of T-cell responses are regulated by a balance of co-inhibitory and co-stimulatory signals, termed immune checkpoints.\textsuperscript{86} Tumours exploit these safety mechanisms to render T cells inactive within the TME. In glioma, higher expression of PD-L1 expression correlates with increasing tumour grade and is associated with poor survival in glioblastoma. A total of 88–100\% of glioblastomas express PD-L1, and it is also expressed on microglia and TAMs within the TME.\textsuperscript{1,86–89} Checkpoint inhibitors are monoclonal antibodies that either inhibit the activity of immune checkpoints, or mimic ligand binding. Checkpoint inhibitors targeting PD-1 (nivolumab/pembrolizumab), PD-L1 (atezolizumab/durvalumab/avelumab) and CTLA-4 (ipilimumab) are licensed for use in various cancers, with pembrolizumab licensed by the FDA for mismatch repair deficient and microsatellite instability-high tumours regardless of the tissue of origin. Although overall nivolumab was overall found not to improve survival in patients with relapsed glioblastoma, a small subset of patients did have a durable response, and analysis of their tumour biomarkers and immune responses may guide future trials.\textsuperscript{84} Initially within this trial, an exploratory cohort of patients were treated with nivolumab and ipilimumab (licensed for use in melanoma), but this combination was less well tolerated compared to nivolumab monotherapy and so was not included in the main trial.\textsuperscript{86} Nivolumab is currently under investigation in combination with radiation ± TMZ in newly diagnosed patients, and trials of other checkpoint inhibitors are ongoing or awaiting final results (Table 2). Early interim reports from phase II trials of pembrolizumab in relapsed glioblastoma and durvalumab with bevacizumab in newly diagnosed/relapsed glioblastoma are encouraging.\textsuperscript{91,92} Checkpoint inhibitors are associated with a variety of immune-mediated toxicities.\textsuperscript{85} Notably for glioblastoma, transient increases in tumour size can occur due to inflammatory infiltrates, which within the fixed size of the cranial vault may
cause raised intracranial pressure, requiring urgent medical or surgical intervention.94

Tumour vaccines

Cancer vaccination is achieved in several ways (Fig. 2). The first involves administering a tumour-specific antigen (or combination of antigens), which can then be trafficked to antigen-presenting cells for presentation to T cells to elicit an immune response. Drawbacks are that it is HLA subtype specific, and that it relies upon expression of the specific antigen within the patient’s tumour.95 The second method is to collect autologous dendritic cells, prime them ex vivo with the patient’s tumour antigens, and then administer them back into the patient intradermally; a process referred to as dendritic cell vaccination.96 The only vaccine therapy to have completed evaluation is rindopepimut, an EGFRvIII-targeted vaccine, which did not improve survival when administered alongside standard therapy in patients with newly diagnosed glioblastoma.85 However, an exploratory outcome found improved survival in patients with significant residual disease. Various vaccines are in earlier stages of development, and discussed more fully elsewhere, with several promising candidates.96 HSPPC-96, an autologous vaccine derived from antigenic tumour peptides bound to heat-shock protein, reported a promising 6 month survival rate of 90% in a phase II trial in 41 patients with recurrent glioblastoma.97 AFTV is an autologous vaccine derived from formalin-fixed tumour samples which reported a favourable 3 year survival rates of 38% in a phase I/II trial in 24 patients with newly diagnosed glioblastoma treated with AFTV in addition to standard therapy.98 A peptide vaccine that selected 4 of 14 pre-selected antigens based upon pre-existing antigen-specific IgG responses has demonstrated the feasibility of personalised vaccines in a phase I trial in 12 patients with recurrent glioblastoma.99

| Target | Therapy | Setting | Phase | Identifier |
|--------|---------|---------|-------|------------|
| Checkpoint inhibitors | PD-1 | Radiotherapy + temozolomide + either nivolumab or placebo | Newly diagnosed | II | NCT02667587 |
| | | Radiotherapy + either nivolumab or temozolomide | Newly diagnosed | III | NCT02617589 |
| | | Radiotherapy + temozolomide + pembrolizumab | Newly diagnosed | I/II | NCT02530502 |
| | | Nivolumab + either high or low dose bevacizumab | Relapsed | II | NCT03452579 |
| | | Pembrolizumab ± bevacizumab | Relapsed | II | NCT02337491 |
| | | Pembrolizumab + surgery | Relapsed | II | NCT02337686 |
| PD-1 + CTLA-4 | Ipilimumab and/or nivolumab in combination with temozolomide | Newly diagnosed | I | NCT02311920 |
| | Nivolumab vs. bevacizumab; Nivolumab ± ipilimumab | Relapsed | III | NCT02017717 |
| | Tumour-treating fields + nivolumab ± ipilimumab | Relapsed | II | NCT03430791 |
| 4-1BB + LAG-3 + PD-1 | Anti-LAG-3 or uralumab ± nivolumab | Relapsed | I | NCT02658981 |
| Dendritic cell vaccine | DCVax-L or placebo with radiotherapy + temozolomide | Newly diagnosed | III | NCT00045968 |
| | ICT-107 or placebo with radiotherapy + temozolomide | Newly diagnosed | III | NCT02546102 |
| | ADCTA-G + radiotherapy + temozolomide | Newly diagnosed | II | NCT02772094 |
| | ICT-121 | Relapsed | I | NCT02049489 |
| Peptide vaccine | Temozolomide + IMAM950 + Poly-ICLC (after radiotherapy) | Newly diagnosed | I/II | NCT01920191 |
| | Bevacizumab ± DSP-7888 | Relapsed | II | NCT03149003 |
| | Temozolomide + APVAC + Poly-ICLC + GM-CSF (after radiotherapy) | Newly diagnosed | I | NCT02492292 |
| | Mutation-derived tumour antigen vaccine + Tumour-treating fields + temozolomide | Newly diagnosed | I | NCT03223103 |
| Adoptive cell therapies | T cell | CMV-specific cytotoxic T cells + temozolomide ± surgery | Relapsed | I/II | NCT02661282 |
| T cell/CAR-T | Anti-Her2 CAR CMV-specific T cells | Relapsed | I | NCT01109095 |
| CAR-T | Anti-IL13Rα2 CAR-T cells | Relapsed | I | NCT02208362 |
| CAR-T | Intracerebral Anti-EGFRvIII CAR-T | Relapsed | I | NCT03283631 |
| CAR-T | Intracranial Anti-Her2 CAR-T Cells | Relapsed | I | NCT0242297 |
| CAR-T | Anti-EGFRvIII CAR-T cells | Relapsed | Pilot | NCT02209376 |
| Viral therapy | Adenovirus | Delta-24-RGD adenovirus | Recurrent | I/II | NCT01582516 |
| Adenovirus | DNX-2401 + temozolomide | Recurrent | I | NCT01765734 |
| Adenovirus | DNX-2401 + pembrolizumab | Recurrent | II | NCT02798406 |
Tumour vaccines

Dendritic cell vaccine

Peptide vaccine

Immune checkpoint inhibitors

Co-stimulatory signal

Co-inhibitory signals

T cell therapies

Virus with CAR construct CAR-T cells

Bevacizumab

Viral therapy

Engineered virus which selectively replicates within cancer cells

Harnessing the immune system in glioblastoma

NF Brown et al.
critical organ dysfunction, which limits use to antigens that are highly tumour specific. In addition, the immunosuppressive TME in solid tumours reduces CAR-T trafficking to the tumour, and subsequent proliferation and persistence.

Early-phase clinical trials in glioblastoma are underway investigating CAR-T therapeutics targeting IL-13 receptor alpha 2 (IL-13Rα2), epidermal growth factor receptor variant III (EGFRvIII) and human epidermal growth factor receptor 2 (Her-2) (Table 2). IL-13Rα2 is abundantly expressed on the majority of glioblastomas in both differentiated and stem-cell-like cells, with limited expression in normal brain. EGFRvIII is a mutated form of wild-type EGFR that is tumour-specific and present in approximately one quarter of patients with glioblastoma. Reported frequency of Her-2 expression in glioblastoma varies greatly from 0 to 42%. Early reports highlight striking responses. Other adoptive cell therapy strategies in early clinical development include cytotoxic T lymphocytes specific for antigens such as cytomegalovirus (present in over 90% of glioblastoma tumours, but not surrounding brain), lymphokine-activated cytotoxic T cells and natural killer cells.

Current approaches to enhancing CAR-T cell therapy in solid tumours include strategies to incorporate additional intracellular signalling domains that enhance proliferation and persistence (e.g. IL-12 secreting armed CARs) and provision of user control over T-cell immune activation to control toxicity, for example conditional CARs that require small molecule activation. CARs have also been inserted into other immune cell subsets (e.g. CAR-NK cells) with promising preclinical reports.

Oncolytic viruses

OVs are native or genetically engineered viruses that promote anti-tumour responses through selective replication within cancers cells resulting in cell lysis or immunogenic cell death. Glioblastoma is susceptible to OVs in preclinical models. Overcoming viral exclusion by the blood–brain barrier has been achieved by direct tumour injection of OVs, or by using viruses known to have good CNS penetration (e.g. parvovirus). Early phase trials have established OVs as safe in glioblastoma, but as yet efficacy has been modest. Current strategies are focussing on targeted OVs and combination therapy (Table 2).

Bevacizumab

Bevacizumab is an anti-VEGF monoclonal antibody. It is used as a steroid-sparing agent in glioblastoma for the management of cerebral oedema, although has not demonstrated a survival benefit and is licensed outside of the EU for this indication. As well as modulating vasculature, VEGF inhibits dendritic cell maturation, antigen presentation, and lymphocyte trafficking into tumours. As such, bevacizumab is finding a new role as an adjunct to immunotherapies, possibly via the normalisation of tumour vasculature and induction of high endothelial venule (HEV) formation within tumours, both of which facilitate T-cell infiltration and activation. Anti-VEGF therapy induces transient vessel normalisation, but studies support that lower doses than those routinely used in clinical practice result in a longer normalisation window. Combination ipilimumab and bevacizumab in patients with melanoma suggests VEGF inhibition enhances anti-tumour immune responses. Several combination anti-VEGF/immunotherapy studies are underway in glioblastoma (Table 2), with interim data from a phase II trial of the anti-PD-L1 agent durvalumab in combination with bevacizumab reporting apparent clinical activity in a subset of bevacizumab-naïve patients.

CONCLUSIONS AND FUTURE DIRECTIONS

Cancer treatment is moving towards personalised care with the ability to therapeutically target-specific tumour characteristics. Immunotherapies currently in clinical development will likely benefit a subset of patients with glioblastoma; however, no reliable biomarker currently exists to predict these patients.

Unlike most cancers, glioblastomas rarely metastasise, affording surgical debulking in glioblastoma may enhance the effectiveness of immunotherapy by diminishing the immunosuppressive TME. Ongoing trials of nivolumab in newly diagnosed glioblastoma that are stratified by the extent of resection may provide insight. If so, the role of surgery may be extended to recurrent disease (when it is not routinely performed) as an adjunct to immunotherapy.

Various devices are available to bypass the BBB and deliver therapies directly into a tumour or tumour cavity, reducing systemic toxicity, and potentially modulating the TME more favourably than systemic treatment. Intracranial administration via catheter delivery is currently under investigation in clinical trials of CAR-T cell therapy, with case reports of clinical efficacy.

There are also new avenues being explored to augment the efficacy of immunotherapy. Recent evidence shows that distinct gut microbial composition, or microbiome can affect and even enhance responses to checkpoint inhibitors, and that depletion of intestinal bacteria with antibiotics can diminish the patient’s response to immunotherapy. Future breakthroughs could manipulate the microbiome towards a status that promotes anti-tumour immune responses. Another growing field is
thermal therapy, with evidence that hyperthermia can mediate immunogenic cell death.\textsuperscript{144} It is also critical that the TME if fully characterised to determine how it can be further targeted for cancer immunotherapy. T-cell metabolism is a developing field, and a promising therapeutic target is IDO, a tryptophan catabolic enzyme overexpressed in several tumour types that is thought to create an immunosuppressive microenvironment by inhibiting T-cell immnity.\textsuperscript{147,148}

Tumour heterogeneity is well characterised in glioblastoma, and may contribute towards immune cell heterogeneity within tumours.\textsuperscript{149,150} Glioblastoma heterogeneity is at least partly maintained by extracellular vesicles (EVs) that contain molecules including DNA, RNA and proteins. The shedding and uptake of these vesicles from tumour cells form an additional communication network capable of modulating the TME. Recent evidence has also shown that PD-L1 is expressed on glioblastoma EVs.\textsuperscript{151,152} Further, vascular heterogeneity exists, with vessel co-option (glioblastoma migration along existing blood vessels) occurring alongside angiogenesis, increasing the complexity of heterogeneity within glioblastoma.\textsuperscript{153} Further research into these factors, including utility of techniques such as single-cell RNA sequencing to characterise both tumour, and immune cell heterogeneity\textsuperscript{154,155} may facilitate a future shift towards more personalised treatment.

In summary, the CNS has an active immune system and glioblastoma employs a number of strategies to evade immune-mediated death. To design therapies that effectively harness the immune system against glioblastoma, a deeper understanding of the complex interactions between tumours and the tightly regulated immune system in the CNS is needed. Future therapies will need to address multi-dimensional challenges including identifying truly tumour-specific antigens to target, increasing tumour immunogenicity, targeting the immune microenvironment and controlling toxicity of therapy.

ACKNOWLEDGEMENTS
N.B. is funded by Cancer Research UK. T.C. is funded by the University College London Hospitals Charity. P.M. is supported by the University College Hospital/University College London Biomedical Research Centre and the National Brain Appeal.

AUTHORS CONTRIBUTIONS
N.B., T.C., D.O. and P.M. wrote, reviewed and edited the manuscript.

ADDITIONAL INFORMATION
Competing interests: P.M. has received honoraria from Bristol-Myers Squibb. The remaining authors declare no competing interests.

REFERENCES
1. Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803–820 (2016).
2. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).
3. Chen, R., Cohen, A. L., Colman, H. Targeted therapeutics in patients with high-grade gliomas: past, present, and future. Curr. Treat. Options Oncol. 17, 42 (2016).
4. Corlby, A. Does the immune system naturally protect against cancer? Front. Immunol. 5, 197 (2014).
5. Coullie, P. G., Van den Eynde, B. J., Van Der Bruggen, P. & Boon, T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 132 (2014).
6. Lakshmii Narendra, B., Shhevendar Reddy, K., Shantikumar, S. & Ramakrishna, S. Immune system: a double-edged sword in cancer. Inflamm. Res. 62, 823–834 (2013).
7. Engelhardt, B. et al. Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol. 132, 317–338 (2016).
8. Heinberger, A. B. & Sampson, J. H. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro. Oncol. 13, 3–13 (2011).
9. Chandramohan, V., Mitchell, D. A., Johnson, L. A., Sampson, J. H. & Bignier, D. N. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol. 9, 977–990 (2013).
10. Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell. 31, 326–341 (2017).
11. Razavi, S. M. et al. Immune system evolution of glioblastomas. Front. Surg. 3, 11 (2016).
12. Reinhard, J., Brösicke, N., Theocharidis, U. & Faischner, A. The extracellular matrix niche microenvironment of neural and cancer stem cells in the brain. Int. J. Biochem. Cell Biol. 81, 174–186 (2016).
13. Wade, A. et al. Proteoglycans and their roles in brain cancer. FEBS J. 280, 2399–2417 (2013).
14. Kundu, S. et al. Heparanase promotes glioma progression and is inversely correlated with patient survival. Mol. Cancer Res. 14, 1243–1253 (2016).
15. Oskarsson, T., Batle, E. & Massagué, J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14, 306–321 (2014).
16. Huang, J.-Y. et al. Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: the role of tenasin-C in immune suppression. J. Immunol. 185, 1450–1459 (2010).
17. Zhou, W. et al. Periostin secreted by glioblastoma stem cells recruit M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 17, 170–182 (2015).
18. Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49–61 (2014).
19. Bowman, R. L. & Joyce, J. A. Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. Immunotherapeutics 6, 663–666 (2014).
20. Chen, Z. et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res. 77, 2266–2278 (2017).
21. Komohara, Y., Ohnishi, K., Kuratsu, J. & Takeya, M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216, 15–24 (2008).
22. De, I. et al. CSF1 overexpression promotes high-grade glioma formation without impacting the polarization status of glioma-associated macrophages and macrophages. Cancer Res. 76, 2552–2560 (2016).
23. Komohara, Y., Mimushi, M. & Takeya, M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 105, 1–8 (2014).
24. Hussain, S. F. et al. The role of human glioma-infiltrating macrophages/microglia in mediating antitumor immune responses. Neuro. Oncol. 8, 261–279 (2006).
25. Brandenburg, S. et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors. Acta Neuropathol. 131, 365–378 (2016).
26. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592 (2008).
27. X.-z, Ye et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J. Immunol. 189, 444–453 (2012).
28. Ponente, S. M. et al. CSF1-R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264 (2013).
29. Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656–661 (2010).
30. Mantovani, A., Bisswas, S. K., Galdiero, M. R., Sica, A. & Locati, M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 229, 176–185 (2013).
31. Venteicher, A. S. et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355, eaal4478 (2017).
32. Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399 (2017).
33. Perng, P. & Lim, M. Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front. Oncol. 9, 153 (2019).
34. Jarry, U. et al. Efficiently stimulated adult microglia cross-prime naive CD8+ T cells injected in the brain. Eur. J. Immunol. 43, 1173–1184 (2013).
35. Roy, L.-O., Poirier, M.-B. & Fortin, D. Transforming growth factor-beta and its implication in the malignancy of gliomas. Target Oncol. 10, 1–14 (2015).
36. Pieper, C., Marek, J. J., Unterberg, M., Schwerdtle, T. & Galla, H.-J. Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vitro. Brain Res. 1550, 1–8 (2014).
37. Valdor, R. et al. Glioblastoma progression is assisted by induction of immuno-suppressive function of pericytes through interaction with tumor cells. Oncotarget 8, 68614 (2017).
38. Di Tomaso, T. et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16, 800–813 (2010).
Harnessing the immune system in glioblastoma

NF Brown et al.

39. Ampie, L., Woolf, E. C. & Dardis, C. Immunotherapeutic advancements for glioblastoma. *Front. Oncol.* **5**, 12 (2015).

40. Leone, P. et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. *J. Natl Cancer Inst.* **105**, 1172–1187 (2013).

41. Bloch, O. et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. *Clin. Cancer Res.* **19**, 3165–3175 (2013).

42. Jacobs, J. F. et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. *Neuro. Oncol.* **11**, 394–402 (2009).

43. Reardon, D. A. et al. Immunotherapy advances for glioblastoma. *Neuro. Oncol.* **16**, 1441–1458 (2014).

44. Grossman, S. A. et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. *Clin. Cancer Res.* **17**, 5473–5480 (2011).

45. Tsai, C. S. et al. Immune responses toconcomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. *Neuro. Oncol.* **13**, 393–400 (2011).

46. Schaeue, D., Xie, M. W., Ratkin, J. A. & McBride, W. H. Regulatory T cells in radiotherapeutic responses. *Front. Oncol.* **2**, 90 (2012).

47. Olmes, M. J. et al. Effects of systemically administered hydrocortisone on the human immunome. *Sci. Rep.* **6**, 23002 (2016).

48. Derer, A. et al. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. *Front. Immunol.* **7**, 610 (2016).

49. Formenti, S. C. & Demaria, S. Radiotherapy and cancer immunotherapy: a paradigm shift. *J. Natl Cancer Inst.* **105**, 256–265 (2013).

50. Demaria, S. & Formenti, S. C. Sensors of ionizing radiation effects on the environment after radiotherapy: mechanisms of resistance and recurrence. *Nat. Rev. Cancer* **15**, 409–425 (2015).

51. Fortemps, S. C. & Demaria, S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. *J. Natl Cancer Inst.* **105**, 256–265 (2013).

52. Mathios, D. et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapeutic in GBM. *Sci. Transl. Med.* **8**, 370ra180 (2016).

53. Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA* **318**, 2306–2316 (2017).

54. Hottinger, A. F., Pachecco, P. & Stupp, R. Tumor treating fields: a novel treatment modality and its use in brain tumors. *Neuro. Oncol.* **18**, 1338–1349 (2016).

55. Lee, S. & Margolin, K. Cytokines in cancer immunotherapy. *Cancers* **3**, 3856–3893 (2011).

56. Rand, R. W. et al. Intratumoral administration of recombinant circularly permuted interleukin-4 (vPseudomonas exotoxin in patients with high-grade glioma. *Clin. Cancer Res.* **6**, 2157–2165 (2000).

57. Zaidi, M. R. & Merlino, G. The two faces of interferon-γ in cancer. *Clin. Cancer Res.* **17**, 6118–6124 (2011).

58. Zhu, V. F., Yang, J., LeBrun, D. G. & Li, M. Understanding the role of cytokines in glioblastoma multiforme pathogenesis. *Cancer Lett.* **316**, 139–150 (2012).

59. Jackson, C., Ruzevick, J., Phallen, J., Belzaid, Z. & Lim, M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. *Clin. Dev. Immunol.* **1**, 1–20 (2011).

60. Reardon, D. A. et al. OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. *Neuro. Oncol.* **19**, ii21–ii27 (2017).

61. Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. *Lancet Oncol.* **18**, 1373–1385 (2017).

62. Wilmutte, R. et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. *Neuroreport* **16**, 1081–1085 (2005).

63. Bergoffen, A. S. et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. *Neuro. Oncol.* **17**, 1064–1075 (2015).

64. Wei, B. et al. The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression. *Tumor Biol.***35**, 2923–2929 (2014).

65. Xue, S., Song, G. & Yu, J. The prognostic significance of PD-L1 expression in gliomas with a meta-analysis. *Sci. Rep.* **7**, 4231 (2017).

66. Omuro, A. et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. *Neuro. Oncol.* **20**, 674–686 (2018).

67. Reardon, D. A. et al. Phase 2 study to evaluate safety and efficacy of MED4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: an update. *J. Clin. Oncol.* **35**, 2042 (2017).

68. Reardon, D. A. et al. ATIM-35. Results of the phase IB keynote-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent PD-L1-positive glioblastoma multiforme (GBM). *Neuro. Oncol.* **18**, wix5–wix6 (2016).

69. Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **28**, iii19–iv142 (2017).

70. Zhu, X. et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. *J. Neurosurg. Pediatr.* **19**, 249–253 (2017).

71. Mellief, C. J., van Hall, T., Arens, R., Ossendorp, F. & van der Burg, S. H. Therapeutic cancer vaccines. *J. Clin. Invest.* **125**, 3401–3415 (2012).

72. Winograd, E. K., Ciesielski, M. J. & Fenstermaker, R. A. Novel vaccines for glioblastoma: clinical update and perspective. *Immunotherapy* **8**, 1293–1308 (2016).
158. Daneman, R. & Prat, A. The blood–brain barrier. Perspect. Biol. 7, a020412 (2015).
159. Dombrowski, Y. et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat. Neurosci. 20, 674 (2017).
160. Laman, J. D. & Weller, R. O. Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J. Neuroimmune Pharmacol. 8, 840–856 (2013).
161. Jessen, N. A., Munik, A. S. F., Lundgaard, I. & Nedergaard, M. The glymphatic system: a beginner’s guide. Neurochem. Res. 40, 2583–2599 (2015).
162. Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337 (2015).
163. Herz, J., Filiano, A. J., Smith, A., Yogev, N. & Kipnis, J. Myeloid cells in the central nervous system. Immunity 46, 943–956 (2017).
164. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314–1318 (2005).